Long-term value

We are building on our solid fundamentals to create long-term value for our stakeholders as a sustainable business partner and a good corporate citizen, using science and innovation to help deliver better health.

Our value creation

Economic value
- Dividends: €3.9bn paid out to our shareholders
- Proposed dividend of €3.20 per share to be submitted for approval to the 2021 Annual General Meeting, the 27th consecutive year in which we have increased our dividend
- Suppliers: €14.8bn Sanofi spend
- Income tax and other taxes paid: €2.4bn

€14.8bn Sanofi spend for suppliers

Scientific value
- Accelerate R&D focus on six potentially transformative medicines in the areas of breast cancer, hemophilia, multiple rare diseases, respiratory syncytial virus and multiple sclerosis: Amcenestrant, Fitusiran, Etanerceptococog alpha2, Venclexta, Nintedanib, Tolliretinib
- 40 projects in phase 3 or submitted to regulatory authorities for approval
- 83 projects in clinical development including 32 new molecular entities

40 projects in phase 3 or submitted to regulatory authorities for approval

Health value
- Pharmaceutical contributions paid to healthcare systems: €5.7bn
- Addressing public health needs:
  - Healthcare access programs: 124 million patients reached via 23 programs in 117 countries
  - Over half a billion people vaccinated worldwide in 2020
  - Medicines and healthcare solutions available in more than 170 countries
- Education for better health: 260,000 healthcare professionals trained
- Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030

23 healthcare access programs across 117 countries

Social value
- Personnel costs: €9bn
- 5.4% of work-study contracts awarded to young people from priority neighborhoods under the PAQTE initiative, the French government’s urban renewal policy
- Gender parity ambition 2025: gender parity among Sanofi senior leaders
- Mobilizing for the planet:
  - Reduction of 22% in water consumption since 2015
  - Reduction of 27% of CO2 emissions since 2015

€9bn personnel costs

1 2019 dividends paid in 2020. 2 In partnership with Swedish Orphan Biovitrum (Sobi). 3 In partnership with AstraZeneca. All data: 2020 unless otherwise indicated.